Meeting
2022 ASCO Genitourinary Cancers Symposium
Prostate-specific antigen (PSA) outcomes in black (B) and white (W) chemotherapy-naïve (CN) prostate cancer (PC) patients (pts) treated with enzalutamide (ENZA).
Authors
Alicia K. Morgans
Dana-Farber Cancer Institute, Boston, MA
Alicia K. Morgans , Agnes Hong , Sharanya Murty , Nader N. El-Chaar , Krishnan Ramaswamy , Anna D. Coutinho , David Nimke , Stephen J. Freedland
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Cancer Disparities
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 20)
DOI
10.1200/JCO.2022.40.6_suppl.020
Abstract #
20
Poster Bd #
A6
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
Response to androgen signaling (AS)-directed therapy after treatment with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of study COU-AA-302.
First Author: Matthew R. Smith
Poster
2019 Genitourinary Cancers Symposium
Timing of docetaxel chemotherapy and impact on outcomes in metastatic castrate-resistant prostate cancer (MCRPC).
First Author: Alastair Thomson
Poster
2019 Genitourinary Cancers Symposium
The association of PSA levels and survival outcomes in patients with chemotherapy-naïve, castration-resistant prostate cancer (CRPC) who were treated with androgen receptor signaling axis targeting agent (ARAT): A Japanese cohort study.
First Author: Tatsuya Shimomura
Poster
2019 Genitourinary Cancers Symposium
Whole blood FOLH1 mRNA expression and treatment response in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Edmond Michael Kwan